Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Galencia_Group
|
| gptkbp:awards |
industry recognition
|
| gptkbp:CEO |
gptkb:Abdul_M._M._K._K._Al-Azzawi
|
| gptkbp:clinicalTrials |
ongoing
iron therapies phase I studies phase II studies phase III studies |
| gptkbp:collaborations |
academic institutions
|
| gptkbp:communityEngagement |
educational initiatives
health awareness campaigns patient support programs |
| gptkbp:communityOutreach |
international markets
strategic alliances distribution networks |
| gptkbp:corporateSocialResponsibility |
sustainable practices
community health healthcare_access |
| gptkbp:employees |
approximately 1,000
|
| gptkbp:financialPerformance |
profitability
publicly traded revenue growth market capitalization |
| gptkbp:focus |
iron deficiency
|
| gptkbp:founded |
2000
|
| gptkbp:headquarters |
gptkb:Zurich,_Switzerland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vifor Pharma
|
| gptkbp:innovation |
advanced manufacturing processes
new drug development patient-centric solutions |
| gptkbp:investmentFocus |
R&D
|
| gptkbp:leadership |
experienced professionals
scientific expertise diverse management team |
| gptkbp:market |
gptkb:Asia
gptkb:Latin_America gptkb:North_America Europe global |
| gptkbp:partnerships |
government agencies
various healthcare organizations biotechnology firms healthcare_providers |
| gptkbp:productLine |
combination therapies
new formulations IV iron therapies oral iron supplements |
| gptkbp:products |
gptkb:Venofer
gptkb:Injectafer Ferinject |
| gptkbp:regulatoryCompliance |
multiple countries
|
| gptkbp:research_areas |
hematology
gastroenterology nephrology |
| gptkbp:researchFocus |
iron metabolism
|
| gptkbp:researchInterest |
clinical guidelines
peer-reviewed journals conference presentations |
| gptkbp:subsidiary |
gptkb:Vifor_Fresenius_Medical_Care_Renal_Pharma
|
| gptkbp:sustainabilityInitiatives |
environmental responsibility
|
| gptkbp:website |
www.viforpharma.com
|